Vor Biopharma: Short On Cash, Too Much Uncertainty For Now
Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2024, as well as ...
Hosted on MSN18h
UCLM routs Benedicto College in CEL Season 3 Valorant tournament
The University of Cebu Lapu-Lapu Mandaue (UCLM) Webmasters lived up to their lofty billing as the defending champions in the ...
CEL-SCI to initiate Multikine cancer trial
CEL-SCI (CVM) announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine in newly ...
CEL-SCI公司推进头颈癌Multikine研究新进展
CEL-SCI首席执行官Geert Kersten对研究前景表示信心，他提到头颈癌医生的积极反应，以及Multikine有望成为新的治疗标准。虽然 InvestingPro 数据显示公司目前EBITDA为负$24.6M且面临盈利挑战，但生物统计学家建议称，鉴于目标人群的选择基于先前研究中获益最大的群体，该研究成功概率超过95%。投资者可通过 InvestingPro ...
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment. Full enrollment expected by Q2 2026 with plans to seek early appr ...